- Pregnancies decline overall, up among older women
- Pentagon plans to destroy Syrian chemical arms on ship at sea
- Paris Metro issues ‘politeness manual’ to improve passengers’ behavior
- Justin Bieber, crew detained at Australian airport in drug search
- Lee Rigby trial: Muslim who machete-hacked soldier calls it ‘humane’ kill
- GM ending Chevy sales in Europe to focus on Opel and Vauxhall
- Putin’s diplomats to U.S. busted for living high life off $1.5M bilked from Medicaid
- Happy Meal: Couple goes to McDonald’s, leaves with bag packed with cash
- Boehner: It took me 3 to 4 hours to sign up for Obamacare
- Oh my God! Costco lists Bible as fiction, Ron Burgundy memoir as gospel
Diabetes drug off market in Europe
FDA puts harsh restrictions on use of Avandia in U.S.
European regulators ordered the diabetes drug Avandia off the market and the Food and Drug Administration placed stringent restrictions on its use in the United States, saying heart attack risks associated with the former blockbuster are too great a safety concern to continue its use for most people.
In simultaneous news briefings Thursday, the European Medicines Agency and the FDA announced their long-awaited decisions on the fate of GlaxoSmithKline’s controversial drug. The European regulator said it would stop authorizing marketing of Avandia, which will be banned from sales within the next few months.
The FDA said new patients will be able to get a prescription for Avandia, but only if they can’t control their blood sugar with other medications. Doctors will have to document that their patients are eligible to receive the drug and have been briefed on its risks. FDA expects the restricted plan “will limit use of Avandia significantly.”
The two decisions will virtually eliminate use of the drug around the world, said Dr. Steve Nissen of the Cleveland Clinic.
“To prescribe this drug in the U.S., you now have to certify that the patient has tried every other diabetes drug, and there are no patients who only respond to Avandia,” said Dr. Nissen, who published the first paper linking Avandia to heart risks.
While there are more than a dozen diabetes drugs on the market, only Actos from Japan-based Takeda Pharmaceuticals works the same way as Avandia. U.S. sales of Actos have risen steadily - hitting $3.4 billion last year - as Avandia’s reputation has soured. Global sales of Avandia have fallen from a peak of $3.2 billion in 2006 to $1.2 billion last year.
In the U.S., more than 2.6 million patients filled prescriptions for Avandia last year, and some experts worry that those currently taking the drug may continue using it despite the risk of heart attack.
Anyone already taking Avandia will need to sign a waiver saying that they understand the drug’s risks. But Dr. Harlan Krumholz of Yale University says patients may not understand they are still at risk even if they feel good.
“Asking a patient, ‘Are you doing well on this medication?’ isn’t an adequate assessment of whether the drug is increasing their risk. It’s a silent risk. They don’t feel the risk,” Dr. Krumholz said.
The safety of Avandia, the brand name for rosiglitazone, has been the top drug safety controversy facing the FDA in recent years. FDA’s critics have framed the Avandia decision as a key test of the agency’s Obama-appointed leadership, who vowed to bolster the agency’s regulatory stance after a series of drug safety problems under the previous administration.
“We are taking somewhat different strategies, but both strategies are designed to assure the goals of safety,” she said in a briefing with reporters.
But critics say the agency had a responsibility to act much sooner. Senate investigators concluded earlier this year that the FDA was informed in 2005 of Avandia’s heart risks - two years before it made those risks public. The same investigators concluded GlaxoSmithKline began hiding evidence about Avandia’s risks soon after it came on the market.
“This unfortunate decision sends a signal to industry that this Food and Drug Administration is incapable of removing a drug from the market,” said Paul Thacker, who led the Senate Finance Committee’s investigation into the handling of Avandia. “I have a hard time imagining another drug where more negative evidence has piled up.”
GlaxoSmithKline said Thursday it will voluntarily stop promoting Avandia in all countries where it operates.
- 'Hunger Games' delivers Obama's message on income inequality: liberal group
- CARSON: Getting to the top by starting at the bottom
- Hack attack: 2 million Facebook, Twitter passwords stolen
- Obama returns to class warfare as poll numbers plunge
- Russian diplomats busted bilking $1.5 million from Medicaid
- NAPOLITANO: Pope Francis should be saving souls, not pocketbooks
- CURL: 'Mission Accomplished' for Obamacare
- Democratic infighting erupts over 'we can have it all' fantasy on entitlements
- Inside China: Nuclear submarines capable of widespread attack on U.S.
- President Obama acknowledges living with illegal immigrant uncle: report
Independent voices from the The Washington Times Communities
NFL junkie Eric Golub reports on his favorite obsession. There is no football offseason. Every February he pretends to care about other sports while sobbing uncontrollably each Sunday until September.
All of the world’s problems, solved on your back porch
Brazen, leading-edge, “call it like it is” columns and reporting from Ohio native, radio host and writer, Sara Marie Brenner.
Entertainment News and Reviews from Washington, D.C. and beyond.
White House pets gone wild!